natgillin/translations-raw huggingface dataset:
The rates of discontinuation due to any adverse reaction were 7.2% in patients receiving INTELENCE and 5.6% in patients receiving placebo.
Pogostnosti ukinitve zdravila zaradi kateregakoli neželenega učinka sta znašali 7,2% pri bolnikih, ki so prejemali zdravilo INTELENCE, in 5,6% pri tistih, ki so prejemali placebo.
The rates of documented symptomatic hypoglycaemia with Trulicity 1.5 mg and 0.75 mg, and exenatide twice daily were 0.19, 0.14, and 0.75 episodes/patient/year, respectively.
Deset bolnikov je poročalo o hudi hipoglikemiji z zdravilom Trulicity 1,5 mg, sedem z zdravilom Trulicity 0,75 mg in petnajst z insulinom glarginom.
The rates of documented symptomatic hypoglycaemia with Trulicity 1.5 mg and 0.75 mg, and insulin glargine were 1.67, 1.67, and 3.02 episodes/patient/year, respectively.
Stopnja dokumentirane simptomatske hipoglikemije za zdravilo Trulicity 1,5 mg in 0,75 mg ter eksenatid dvakrat na dan je bila 0,19, 0,14, in 0,75 epizod/bolnika/leto.
The rates of documented symptomatic hypoglycaemia with Trulicity 1.5 mg and 0.75 mg, and sitagliptin were 0.19, 0.18, and 0.17 episodes/patient/year, respectively.
Stopnja dokumentirane simptomatske hipoglikemije za zdravilo Trulicity 1,5 mg in 0,75 mg ter insulin glargin je bila 1,67, 1,67, in 3,02 epizod/bolnika/leto.
The rates of events in the composite endpoint were low across all treatment groups and were similar or lower for each of the active treatments compared to placebo.
Deleži sestavljenega opazovanega dogodka so bili majhni v vseh zdravljenih skupinah in so bili podobni ali manjši za vsako zdravljenje z zdravilno učinkovino v primerjavi s placebom.
The rates of gout flare requiring treatment were low and comparable to placebo in the last 6 months of the randomised trials (after gout flare prophylaxis was discontinued) with median scores of zero.
Delež napadov protina, ki so zahtevali zdravljenje, je bil v zadnjih 6 mesecih randomiziranih preskušanj (po prenehanju uporabe profilakse napadov) majhen in podoben kot pri placebu; mediani seštevek je bil nič.
The rates of Grade 3-4 IRRs (which occurred in relatively few patients) were similar before and after mitigation measures were implemented.
Pogostnost reakcij, povezanih z infuzijo, stopnje 3-4 (ki se je pojavila pri relativno majhnem številu bolnikov) je bila podobna pred in po uvedbi ukrepov za blažitev.
The rates of MMR in the SPRYCEL and imatinib treatment groups, respectively, within 3 months (8% and 0.4%), 6 months (27% and 8%), 9 months (39% and 18%),
Deleži MMR v skupini, ki je prejemala zdravilo SPRYCEL in v skupini, ki je prejemala imatinib, so bili v 3 mesecih (8% oziroma 0,4%), 6 mesecih (27% oziroma 8%), 9 mesecih (39% oziroma 18%), 12 mesecih (46% oziroma
The rates of outcome events including, major bleed and other bleeding events were consistent with those seen in RE-LY.
Stopnje opazovanih dogodkov, ki so zajemali velike in druge krvavitve, se niso razlikovale od njihovih ugotovljenih v raziskavi RE-LY.
The rates of premature study discontinuation, adverse events overall (and infections, specifically), and biopsy-proven acute liver graft rejection at 12 months were all significantly greater in the sirolimus conversion group compared to the CNI continuation group.
Pogostnost prezgodnje prekinitve študije, vseh neželenih učinkov skupaj (še posebej okužb) in dokazana akutna zavrnitev presajenih jeter po 12 mesecih z biopsijo je bila statistično pomembno večja v skupini s prehodom na sirolimus kot v skupini, ki je nadaljevala s CNI.
The rates of response for the two treatment arms are reported in Table 10.
Deleži odzivov v obeh terapevtskih krakih so navedeni v preglednici 10.
The rates of treatment-related adverse events resulting in discontinuation were 14% in CP-CML, 7% in AP-CML and 4% in BP-CML/Ph+ ALL.
Stopnje pojavnosti neželenih učinkov zaradi zdravljenja, zaradi katerih je bilo treba zdravljenje prekiniti, so bile 14 % za CP-KML, 7 % za AP-KML in 4 % za BP-KML/Ph+ ALL.
The ratio is for Tresiba Flex/Tresiba.
6 To je razmerje med Tresiba Flex/Tresiba.
The ratio of patients with basal versus squamous cell skin cancers (4:1) is comparable with the ratio expected in the general population (see section 4.4).
Delež bolnikov z bazalnoceličnim karcinomom proti ploščatoceličnim karcinomom kože (4:1) je primerljiv pričakovanemu deležu v splošni populaciji (glejte poglavje 4.4).
The ratio of the exacerbation rate for fluticasone furoate/vilanterol 92/22 micrograms versus FF 92 was 0.755 (95% CI 0.603, 0.945).
Razmerje deležev poslabšanj z flutikazonfuroatom/vilanterolom 92/22 mikrogramov in s FF 92 mikrogramov je bilo 0,755 (95 % IZ 0,603, 0,945).
The rational basis for treatment consists of restoration of the bile acid- dependent component of bile flow enabling restoration of biliary secretion and biliary elimination of toxic metabolites; inhibition of the production of the toxic bile acid metabolites by negative feedback on cholesterol 7α-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis; and improvement of the patient’s nutritional status by correcting intestinal malabsorption of fats and fat-soluble vitamins.
Osnova zdravljenja je obnova sestavnega dela toka žolča, ki je odvisen od žolčne kisline in omogoča obnovitev biliarne sekrecije žolča in biliarnega izločanja toksičnih presnovkov; zaviranje nastajanja toksičnih presnovkov žolčnih kislin z negativno povratno zanko do holesterol-7α-hidroksilaze, ki omejuje sintezo žolčne kisline; in izboljšanje prehranskega statusa bolnika z odpravo intestinalne malabsorpcije maščob in vitaminov, topnih v maščobah.
The rational basis for treatment consists of restoration of the bile acid- dependent component of bile flow enabling restoration of biliary secretion and biliary elimination of toxic metabolites; inhibition of the production of the toxic bile acid metabolites by negative feedback on cholesterol 7α-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis; and improvement of the patient’s nutritional status by correcting intestinal malabsorption of fats and fat-soluble vitamins.
Osnova zdravljenja je obnova sestavnega dela toka žolča, ki je odvisen od žolčnih kislin in omogoča obnovitev biliarne sekrecije izločanja in biliarnega izločanja toksičnih presnovkov; zaviranje nastajanja toksičnih presnovkov žolčne kisline z negativno povratno zanko do holesterol-7α-hidroksilaze, ki omejuje sintezo žolčne kisline; in izboljšanje prehranskega statusa bolnika z odpravo intestinalne malabsorpcije maščob in vitaminov, topnih v maščobah.
The rationale for administration of Kuvan in patients with BH4-responsive PKU is to enhance the activity of the defective phenylalanine hydroxylase and thereby increase or restore the oxidative metabolism of phenylalanine sufficient to reduce or maintain blood phenylalanine levels, prevent or decrease further phenylalanine accumulation, and increase tolerance to phenylalanine intake in the diet.
Osnovni princip zdravljenja z zdravilom Kuvan pri bolnikih s PKU, ki se odzivajo na BH4 je povečati aktivnost okvarjene fenilalanin hidroksilaze in tako povečati ali obnoviti oksidativno presnovo fenilalanina tako, da ta zniža ali ohrani ravni fenilalanina v krvi, prepreči ali zmanjša nadaljne kopičenje fenilalanina ter poveča odpornost organizma na fenilalanin vnesen s hrano.
The rationale for enzyme replacement therapy is to restore a level of enzymatic activity sufficient to clear the accumulating substrate in the organ tissues; thereby, preventing, stabilizing or reversing the progressive decline in function of these organs before irreversible damage has occurred.
Temeljno vodilo encimske nadomestne terapije je ponovna vzpostavitev takšne encimske aktivnosti, ki bo zadoščala za očiščenje nakopičenega substrata v tkivih organov in na ta način preprečevala, stabilizirala ali odpravljala progresivno nazadovanje delovanja teh organov, preden pride do nepopravljivih poškodb.
The rationale for prescription should be tailored to the individual needs of the cat, based on clinical assessment, the animal’s lifestyle and on the local epidemiological situation (including zoonotic risks, where relevant) in order to address exclusively situations of mixed infestations/risk of infestation.
Predpisovanje zdravila naj bo prilagojeno individualnim potrebam mačke in naj temelji na klinični oceni življenjskega sloga mačke in lokalnega epidemiološkega stanja (vključno z zoonotičnimi tveganji, kjer je potrebno), da je zagotovljeno zdravljenje izključno mešanih infestacij/tveganja za mešane infestacije.
The ratios (13 to 17 years/Adults) for AUC, the end of infusion concentration and the concentration at the midpoint of the dosing interval were 0.99, 1.20, and 0.84, respectively.
Razmerje (od 13 do 17 let/odrasli) vrednosti AUC je znašalo 0,99, razmerje koncentracije ob koncu infuzije 1,20 ter razmerje koncentracije na sredini odmernega intervala 0,84.
The ratios of geometric least-square means of month 6-to-baseline pharmacokinetic were 107%, 100% and 104% for recovery, AUCt and AUC, respectively.
Kvocienti geometrijskih povprečij najmanjših kvadratov farmakokinetike po 6 mesecih proti izhodišču so bili 107 % za zvečanje aktivnosti, 100 % za AUCt in 104 %, za AUC.
The ratios of geometric least-square means of ReFacto AF-to-ReFacto were 100.6%, 99.5% and 98.1% for recovery, AUCt and AUC∞ (area under the plasma concentration curve from time zero to infinity), respectively.
Kvocienti geometrijskih povprečij najmanjših kvadratov zdravila ReFacto AF proti zdravilu ReFacto so bili 100,6 % za zvečanje aktivnosti, 99,5 % za AUCt in 98,1 %, za AUC (površina pod krivuljo plazemske koncentracije od časa nič do neskončnosti).
The ratios of the main metabolite M1 (des-(Orn8, Gly-NH 9)-[Mpa1, D-Tyr(Et)2, Thr4]-oxytocin) to atosiban concentrations in plasma were 1.4 and 2.8 at the second hour and at the end of the infusion respectively.
Razmerje med koncentracijo glavnega presnovka M1 (des-(Orn8, Gly-NH 9)-[Mpa1, D-Tyr(Et)2, Thr4]-oksitocin) in atosibana v plazmi je bilo po dveh urah 1,4 in na koncu infundiranja 2,8.
The ratios of the main metabolite M1 (des-(Orn8, Gly-NH2 9) -29)-[Mpa1, D-Tyr(Et)2, Thr4]-oxytocin) to atosiban concentrations in plasma were 1.4 and 2.8 at the second hour and at the end of the infusion respectively.
Razmerje med koncentracijo glavnega presnovka M1 (des-(Orn8, Gly-NH2 9) -29)-[Mpa1, D-Tyr(Et)2, Thr4]-oksitocin) in atosibana v plazmi je bilo po dveh urah 1,4 in na koncu infundiranja 2,8.
The RE-LY extension study (RELY-ABLE) provided additional safety information for a cohort of patients which continued the same dose of dabigatran etexilate as assigned in the RE-LY trial.
V podaljšku raziskave RE-LY (RELY-ABLE) so pridobili dodatne podatke o varnosti v kohorti bolnikov, ki so nadaljevali z jemanjem enakega odmerka dabigatran eteksilata, kot je bil predpisan v raziskavi RE-LY.
The RE-LY study demonstrated that dabigatran etexilate, at a dose of 110 mg twice daily, is non-inferior to warfarin in the prevention of stroke and SEE in subjects with atrial fibrillation, with a reduced risk of ICH, total bleeding and major bleeding.
Raziskava RE-LY je pokazala, da je dabigatran eteksilat v odmerku po 110 mg dvakrat na dan, pri preprečevanju možganske kapi in sistemskih emboličnih dogodkov pri bolnikih z atrijsko fibrilacijo enakovreden varfarinu in da zmanjša tveganje intrakranialnih krvavitev, vseh krvavitev in velikih krvavitev.
The reaction gradually reduced and disappeared without need for treatment.
Reakcija tkiva se počasi zmanjšuje in izgine brez potrebe po zdravljenju.
The reaction is greatest at two to three days after injection, but the area affected should not be larger than 3 by 8 cm.
Reakcija je najhujša dva do tri dni po injiciranju, vendar pa prizadeto območje običajno ni večje od 3 krat 8 cm.
The reaction is maximal at 2–3 days post vaccination with a maximum area of 3 cm by 8 cm.
Reakcija je največja 2 do 3 dni po cepljenju in ima največjo površino 3 krat 8 cm.
The reaction reduced and disappeared without need for treatment.
Reakcija tkiva se zmanjšuje in izgine brez potrebe po zdravljenju.
The reactions are listed following the MedDRA frequency convention.
Neželeni učinki so našteti v skladu s dogovorom o navedbi pogostnosti po MedDRA.
The reactions included injection site erythema, injection site haematoma and injection site pain (see also section 5.3).
Reakcije so vključevale rdečino na vbodnem mestu, hematom na vbodnem mestu in bolečino na vbodnem mestu (glejte tudi poglavje 5.3).
The reactions may last for at least 47 days in the form of diffuse swelling of less than 2 cm diameter.
Reakcija v obliki difuzne otekline premera manj kot 2 cm lahko traja najmanj 47 dni.
The reactions may persist for at least 97 days in the form of small granules of less than 0.5 cm of diameter.
Reakcija v obliki manjšega granuloma, premera manj kot 0,5 cm lahko traja najmanj 97 dni.
The reactions normally disappear after a few hours when you remove the patch.
Reakcije ponavadi izginejo nekaj ur po odstranitvi obliža.
The reactions normally disappear after a few hours when you remove the patch.
Te reakcije navadno izginejo nekaj ur po odstranitvi obliža.
The reactogenicity profile and rates of adverse events among subjects aged 56-65 years who received Menveo (N=216), were similar to that observed in Menveo recipients subjects aged 11-55.
Profil reaktogenosti in stopnje neželenih učinkov med osebami, starimi med 56-65 leti, ki so dobili cepivo Menveo (n = 216) so bile podobne tistim, ki so jih opazili pri osebah, cepljenih s cepivom Menveo, starih med 11-55 let.
The reactogenicity profile of Fendrix in healthy subjects was generally comparable to that seen in pre- haemodialysis and haemodialysis patients.
Reaktogeni profil cepiva Fendrix pri zdravih osebah je bil na splošno primerljiv s tistim pri predhemodializnih in hemodializnih bolnikih.
The readily prepared Zoledronic acid medac infusion solution should preferably be used immediately.
Razredčeno infuzijsko raztopino zdravila Zoledronska kislina medac morate po možnosti porabiti takoj.
The readily prepared Zoledronic Acid Teva infusion solution should preferably be used immediately.
Razredčeno raztopino zdravila Zoledroniska kislina Teva je najbolje raztopino za infundiranje uporabiti takoj.
The readministration of propranolol may be considered when the child has fully recovered; in case of reoccurrence, treatment should be permanently discontinued.
S ponovnim dajanjem propranolola lahko nadaljujemo, ko otrok popolnoma ozdravi; če se znova pojavi, je treba zdravljenje trajno prekiniti.
The readout for PT is to be done in seconds, because the INR (International Normalised Ratio) is only calibrated and validated for coumarins and cannot be used for any other anticoagulant.
Protrombinski čas je treba odčitati v nekaj sekundah, kajti INR (International Normalised Ratio – mednarodno umerjeno razmerje) je kalibriran in validiran samo za kumarine in se ga ne more uporabljati za meritve učinkov drugih antikoagulacijskih zdravil.
The reason for the reduced clinical efficacy observed in these patients is unknown.
Vzrok za manjšo klinično učinkovitost pri teh bolnikih ni znan.
The reason for this accumulation is unknown, but maybe due to accumulation of florbetaben (18F) or to any of its radioactive metabolites, or to blood radioactivity.
Razlog tega privzema ni znan, morda pa je posledica kopičenja [18F]florbetabena, katerega od njegovih radioaktivnih presnovkov ali radioaktivnosti krvi.
The reason of this difference is unknown.
Vzrok za to razliko ni znan
The reason that this action helps patients with arthritis and psoriasis is not completely understood, but the benefits of methotrexate are thought to be due to its ability to reduce inflammation and suppress an overactive immune system.
Ni popolnoma znano, zakaj ta ukrep pomaga bolnikom z artritisom in psoriazo, domneva pa se, da so koristi metotreksata posledica njegove sposobnosti zmanjševanja vnetja in zaviranja čezmerno aktivnega imunskega sistema.
The Rebif initiation package corresponds to the patient needs for the first month of treatment.
Pakiranje zdravila Rebif za začetek zdravljenja ustreza bolnikovim potrebam prvi mesec zdravljenja.
The Rebif initiation packs correspond to the patient needs for the first month of treatment.
Pakiranje zdravila Rebif za začetek zdravljenja ustreza bolnikovim potrebam prvi mesec zdravljenja.
The reclosable bottle cap should be discarded when the bottle is empty or after 3 days following opening even if the bottle is not empty.
Zamašek z nastavkom za brizgo je treba zavreči, ko je steklenica prazna, ali tri dni po odprtju, tudi če steklenica ni prazna.
The recombinant factor IX portion is identical to the Thr148 allelic form of plasma- derived factor IX.
Delež rekombinantnega faktorja IX je enak alelni obliki Thr148 iz plazme pridobljenega faktorja IX.
The recombinant human hyaluronidase should be clear and colourless.
Raztopina rekombinantne humane hialuronidaze mora biti bistra in brezbarvna.
The recombinant vaccine virus has potential marker properties for use in DIVA (differentiation between field virus infected and solely vaccinated animals).
Rekombinantno cepivo ima potencialne lastnosti markerja za uporabo kot DIVA cepivo (DIVA, ang. differentiation between field virus infected and solely vaccinated animals – razlikovanje med živalmi, ki so se okužile s terenskim virusom in tistimi, ki so bile samo cepljene).
The recomended dose of Ifirmacombi 300 mg /12.5 mg is one tablet a day.
Priporočeni odmerek zdravila Ifirmacombi 300 mg/12,5 mg je ena tableta na dan.
The recommend dose of Pemetrexed medac is 500 mg for every square metre of your body’s surface area.
Priporočeni odmerek zdravila Pemetreksed medac je 500 mg za vsak kvadratni meter površine vašega telesa.
The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2).
Priporočilo za uporabo odmerka 15 mg je glede na farmakokinetični model in ga niso preučevali v tem kliničnem programu (glejte poglavja 4.4, 5.1 in 5.2).
The recommendation of a minimum yield of ≥ 2.0 x 106 CD34+ cells/kg is based on published experience resulting in adequate haematologic reconstitution.
Najmanjši priporočeni delež ≥ 2,0 x 106 CD34+ celic/kg temelji na objavljenih podatkih, po katerih so dosegli zadostno hematološko obnovo.
The recommendations for darunavir boosted with ritonavir are adequate also for darunavir boosted with cobicistat with regard to substrates of CYP3A4, CYP2D6, P-glycoprotein, OATP1B1 and OATP1B3 (see contraindications and recommendations presented in the section above).
Za substrate CYP3A4, CYP2D6, P-glikoprotein, OATP1B1 in OATP1B3 so priporočila enaka, kot za darunavir, okrepljen z ritonavirjem (glejte kontraindikacije in priporočila. navedena v prejšnjih odstavkih).
The recommendations for monitoring of cutaneous reactions, and for discontinuation of INCIVO, ribavirin and peginterferon alfa are summarised in the table below:
Priporočila za spremljanje kožnih reakcij in ukinitev zdravil INCIVO, ribavirin in peginterferon alfa so povzeta v spodnji preglednici.
The recommendations provided under “Clinical comment” in Table 1 are based on drug interaction studies, clinical relevance, or predicted interactions due to elimination pathways.
Priporočila, navedena pod podnaslovom “Klinični komentar” v preglednici 1, temeljijo na študijah interakcij med zdravili, klinični pomembnosti ali napovedanih interakcijah zaradi poti izločanja.
The recommended 2 mg/kg dose, instead of the recommended single administration, was given twice two days apart (10 patients) and three times within two weeks (1 patient) without any notable adverse reactions being reported.
Priporočeni odmerek zdravila 2 mg/kg, namesto priporočenega enkratnega odmerka, dan dvakrat (10 bolnikom) v razmaku dveh dni, in trikrat 2 mg/kg, dane (1 bolniku) v času dveh tednov, so bolniki prenašali brez opaznih neželenih učinkov.
The recommended 24-hour trough concentration ranges for sirolimus are based on chromatographic methods.
Priporočeni razponi 24-urnih najnižjih koncentracij v stanju dinamičnega ravnovesja temeljijo na kromatografskih metodah.
The recommended activity for an adult is 185 MBq of flutemetamol (18F) administered intravenously (as a bolus within approximately 40 seconds).
Priporočena aktivnost za odraslega je 185 MBq flutemetamola (18F), apliciranega intravensko (kot bolus v roku približno 40 sekund).
The recommended activity of technetium (99mTc) besilesomab should be between 400 MBq and 800 MBq.
Priporočena aktivnost tehnecijevega (99mTc) besilesomaba mora biti med 400 MBq in 800 MBq.
The recommended adult dose is 0.25 mg of Fab fragment labelled with 900 ± 200 MBq of technetium
Priporočeni odmerek za odrasle je 0,25 mg Fab' fragmenta, označenega z 900  200 MBq tehnecijevega
The recommended adult dose is:
Priporočeni odmerek je:
The recommended adult dose:
Običajni odmerek za odrasle
The recommended and maximum dose is 0.5 mg/kg / week and should not be exceeded.
Priporočeno in največje odmerjanje je 0,5 mg/kg enkrat na teden in ga ni dovoljeno prekoračiti.
The recommended anti-infective prophylaxis treatment appears to be effective in reducing the risk of PCP and herpes infections (see section 4.4).
Kaže, da priporočena protimikrobna zaščita učinkovito zmanjša tveganje za PCP in okužbo s herpes zostrom (glejte poglavje 4.4).
The recommended course of Rienso is based on the patient’s pre-treatment haemoglobin and body weight as provided in Table 1.
Priporočeni potek zdravljenja z zdravilom Rienso temelji na vrednosti hemoglobina pred zdravljenjem in telesni masi bolnika, kot je prikazano v preglednici 1.
The recommended course of treatment is 3 doses at approximately 2 week intervals.
Priporočeni potek zdravljenja je 3 odmerke v približno 2-tedenskih intervalih.
The recommended daily dose is 0.34 ml per kilogram body weight.
Priporočeni dnevni odmerek znaša 0,34 ml na kilogram telesne mase.
The recommended daily dose is 12°capsules (3°g of the active ingredient) taken as 2°separate doses.
Priporočeni dnevni odmerek je 12 kapsul (3 g učinkovine), razdeljenih na dva posamezna odmerka.
The recommended daily dose is 20mg once a day.
Priporočen dnevni odmerek je 20 mg enkrat dnevno.
The recommended daily dose is 6 to 8 mg per kg for a child with a body weight of up to 55 kg or 300 to 500 mg for a child with a body weight more than 55 kg (which ever dose is lower) taken once a day.
Priporočeni dnevni odmerek je 6 do 8 mg na kg za otroka s telesno maso do 55 kg ali 300 do 500 mg za otroka s telesno maso več kot 55 kg (tisti odmerek, ki je manjši) enkrat na dan.
The recommended daily dose is between 300 mg and 500 mg.
Priporočeni dnevni odmerek je med 300 mg in 500 mg.
The recommended daily dose is calculated according to body surface area, as 1.30 g per m2 divided
Priporočen dnevni odmerek se izračuna glede na telesno površino in znaša 1,30 g na m2, daje pa se ga v dveh deljenih odmerkih vsakih 12 ur.
The recommended daily dose of 12.5 mg/kg body weight corresponds to the Maximum Tolerated Dose (MTD) that was derived from repeat dose toxicity studies in healthy Beagle dogs.
Priporočeni dnevni odmerek 12,5 mg/kg telesne mase ustreza največjemu tolerančnemu odmerku (MTD – Maximum Tolerated Dose), ki je bil izpeljan iz toksikoloških študij s ponovljenimi odmerki, izvedenih z zdravimi psi pasme Beagle.
The recommended daily dose of Kisplyx is 18 mg once a day (one 10 mg capsule and two 4 mg capsules) in combination with one 5-mg tablet of everolimus once a day.
Priporočeni odmerek zdravila Kisplyx je 18 mg enkrat na dan (1 kapsula po 10 mg in 2 kapsuli po 4 mg) skupaj z eno 5-miligramsko tableto everolimusa enkrat na dan.
The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily following treatment with a parenteral anticoagulant for at least 5 days.
Priporočeni dnevni odmerek zdravila Pradaxa je 300 mg, to je ena kapsula po 150 mg dvakrat na dan po zdravljenju s parenteralnim antikoagulantom, ki naj traja najmanj 5 dni.
The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily.
Priporočeni dnevni odmerek zdravila Pradaxa je 300 mg v eni kapsuli po 150 mg dvakrat na dan.